Thermo Fisher Scientific’s PPD clinical research unit formed a strategic partnership with Datavant to enable privacy‑preserving linkage of de‑identified research datasets with real‑world patient records. The agreement leverages Datavant’s tokenization to connect data across more than 350 RWD partners and 80,000 U.S. healthcare sites. Thermo Fisher said the integration will support RWD enrichment for randomized trials, registry analytics, and bespoke evidence generation—aiming to improve recruitment, endpoint validation and post‑market surveillance. The collaboration targets improved operational efficiency for sponsors and better trial design informed by clinical practice data. As regulators and payers demand richer real‑world evidence, the partnership could accelerate hybrid trials and reduce time to insights while spotlighting data governance, privacy compliance and interoperability as critical operational priorities.